EAU 2019: The Role of (fast) Bi-Parametric MRI versus Multi-Parametric MRI and TRUS-biopsy for Detecting Clinically Significant Prostate Cancer in Biopsy Naïve Men with Elevated PSA

Barcelona, Spain (UroToday.com) Professor Barentsz presented his group’s work assessing fast bi-parametric MRI for detection of prostate cancer. As Dr. Barentsz notes, we have three level 1a prospective clinical trials concluding that we should be doing an MRI before biopsy1-3. This is now reflected in the EAU guidelines, noting in biopsy naïve patients:

  • Perform mpMRI before prostate biopsy (1a, weak)
  • When mpMRI is positive (ie. PI-RADS ≥3), combine targeted and systematic biopsies (2a, strong)
  • When mpMRI is negative (ie. PI-RADS ≤2), and clinical suspicion of prostate cancer is low, omit biopsy based on shared decision making with the patient (2a, weak)
A mpMRI is comprised of an injection of contrast, ADC images, T2W images, DCE images; these are obtained in sagittal, coronal and axial planes allowing ~2 studies per hour to be performed in the MRI suite. A bi-parametric MRI removes the DCE images by eliminating contrast injection allowing ~3 to be performed per hour. A fast bi-parametric MRI is a bi-parametric MRI without the T2W sagittal and coronal views (ie. only axial), thus allowing 4 MRIs per hour. 

EAU2019 UroToday fast bpMRI


The aim of the current study was to compare mono-planar “fast” bpMRI, tri-planar bpMRI and mpMRI. This cohort was a subgroup of the 626 patients in the 4M prospective, multi-center, head-to-head trial3. The reference standard was the results of a systematic biopsy and in-bore MR-guided biopsy, as well as a PI-RADS score from the mpMRI (prior to fast bpMRI).

Dr. Barentsz group found that the fast bpMRI group had an 11% rate of PI-RADS 3 compared to 6% in the mpMRI group. Between the three arms (fast bpMRI, bpMRI, mpMRI), there was no difference in detection of clinically significant prostate cancer (sensitivity 95%); fast bpMRI resulted in a 2% increase in the number of men receiving a biopsy. Specificity was 69% in the mpMRI group and 66% in the fast bpMRI group.

Dr. Barentsz notes that there are several pros for fast bpMRI:
  • The ability to perform 4 fast bpMRIs per hour
  • There is a 54% decrease in direct costs, however, the total cost (secondary to increased biopsies and overdiagnosis) equalizes the cost savings
  • There is no contrast given, thus eliminating the risk of an allergic reaction or Gadolinium-brain deposition
However, there are several cons/limitations to fast bpMRI:
  • A 5% absolute increase in PI-RADS 3 lesions (6% vs 11%); however, PRECISION [2] had 7%
  • A 2% absolute increase in the number of biopsies (51% vs 53%)
  • A 1% absolute increase in clinically insignificant prostate cancer (13% vs 12%); however, TRUS systematic biopsy has 23%
  • No histology from mpMRI negative lesions
  • The systematic biopsy as positive was the reference standard
  • Expert center: limited generalizability
Dr. Barentsz concluded that fast bpMRI has equal detection rate for clinically significant prostate cancer and can be fast, non-invasive, accurate and less expensive. He foresees a possible PSA-MRI screening modality that he has termed the mannogram:
EAU2019 UroToday mannogram


Presented by: Jelle Barentsz, MD, PhD, Radboudumc, Nijmegen, The Netherlands

Written by: Zachary Klaassen, MD, MSc – Assistant Professor of Urology, Georgia Cancer Center, Augusta University - Medical College of Georgia Twitter: @zklaassen_md at the 34th European Association of Urology (EAU 2019) #EAU19 conference in Barcelona, Spain, March 15-19, 2019.

References:
  1. Rouviere O, Renard-Penna R, Claudon M, et al. Use of prostate systematic and targeted biopsy on the basis of multiparametric MRI in biopsy-naïve patients (MRI-FIRST): A prospective, multicentre, paired diagnostic study. Lancet Oncol 2019 Jan;20(1):100-109.
  2. Kasivisvanathan V, Rannikko AS, Borghi M, et al. MRI-targeted or standard biopsy for prostate cancer diagnosis. N Engl J Med 2018;378(19):1767-1777.
  3. van der Leest M, Cornel E, Israel B, et al. Head-to-head comparison of transrectal ultrasound-guided prostate versus multiparametric prostate resonance imaging with subsequent magnetic resonance-guided biopsy in biopsy-naïve men with elevated prostate-specific antigen: A Large Prospective multicenter study. Eur Urol. 2018 Nov 23 [Epub ahead of print].
Further Related Content:
Read the Discussion on this Presentation by Dr. Alberto Briganti 
E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe